|
| | | | | | | | | | |
| Name | Indication | Mechanism | Economics | Approved | IP | | Price | 763.85 | |
| Trulicity (dulaglutide) | Type 2 Diabetes | GLP-1 | 1 | 9/18/2014 | | | Shares | 950.164452 | Q423 |
| Zepbound (tirzepatide) | Obesity | GLP-1/Glucagon | 1 | 11/8/2023 | | | MC | 725783.1166602001 | |
| Mounjaro (tirzepatide) | Type 2 Diabetes, NASH | GLP-1/Glucagon | 1 | 5/13/2022 | | | Cash | 5979.9 | Q423 |
| Basaglar (insulin glargine) | Type 2 Diabetes | Insulin Analog | BI | 12/16/2015 | | | Debt | 25225.3 | Q423 |
| Jardiance (empagliflozin) | Type 2 Diabetes | SGLT2 | BI | 8/1/2014 | | | EV | 745028.5166602001 | |
| Tradjenta (linagliptin) | Type 2 Diabetes | DPP4 | BI | 5/2/2011 | | | | | |
| Taltz (ixekizumab) | Psoriasis | IL-17 mab | 1 | 3/22/2016 | | | CEO: David Ricks | | |
| Emgality (galcanezumab) | Migraine | CGRP | | 9/27/2018 | | | CFO: Anat Ashkenazi | | |
| Jaypirca (pirtobrutinib) | CLL/SLL | BTK inhibitor | 1 | 1/27/2023 | | | R&D: Daniel Skovronsky | | |
| Verzenio (abemaciclib) | Breast Cancer | CDK | | 9/28/2017 | | | EVP Loxo: Jacob Van Naarden | | |
| Tyvyt (sintilimab) | Oncology | PD-1 | Innovent | China | | | CMO: David Hyman | | |
| Retevmo (selpercatinib) | | | | 5/8/2020 | | | | | |
| Olumiant (baricitinib) | RA, AA | JAK1/2 | INCY | 5/31/2018 | | | | | |
| Forteo (teriparatide) | Osteoporosis | | 100%? | 11/26/2002 | 2 generics in US | | | | |
| Cymbalta (duloxetine) | Depression | SNRI | 1 | 8/3/2004 | Generic in US. 2013 | | LillyDirect | | |
| Cialis (tadalafil) | ED | PDE5 | 1 | 11/21/2003 | 2016 | | | | |
| Alimta (pemetrexed) | Cancer | | 1 | 2/4/2004 | 2016 | | | | |
| Ebglyss (lebrikizumab) | Atopic Dermatitis | IL-13 mab | ALM in EU, CRL in US | CRL | | | Acquisitions | | |
| Baqsimi (glucagon) | Hypoglycemia | glucagon | | 7/24/2019 | | | POINT Biopharma Global Inc | | |
| Humalog (insulin lispro) | Type 2 Diabetes | Insulin | 100%? | 6/14/1996 | 2013 | | Mablink Biosciences SAS | | |
| Omvoh (mirikizumab) | Crohn's, UC | IL-23 mab | 100%? | 10/26/2023 | | | | | |
| Humulin | Type 2 Diabetes | Insulin | 100%? | 10/28/1992 | | | BD | | |
| Cyramza (ramucirumab) | Gastric Cancer | VEGFR2 mab | 100%? | 4/21/2014 | | | Beam Therapeutics | | |
| | | | | Phase | | | | | |
| donanemab | Alzheimer's | A-B antibody | 1 | III | | | | | |
| LY2062430 (solanezumab) | Alzheimer's | A-B antibody | 1 | III | Antibody | | | | |
| Imlunestrant | mBC | | | III | | | | | |
| liprotamase | Pancreatic Enzyme Replacement | ERT | 100%? | CRL | | | | | |
| R552 | Autoimmune | RIPK | RIGL | I | | | | | |
| GRC 6211 | Pain | TRPV1 | Glenmark | II | | | | | |
| mazdutide | | | | | | | | | |
| insulin efsitora | | | | | | | | | |
| orforglipron | | | | | | | | | |
| bimagrumab | | | | | | | | | |
| LY2157299 | HCC | TGF-BR kinase | 100%? | II | | | | | |
| LY2090314 | AML | GSK3B | 100%? | II | | | Germany injectable manufacturing site | | |
| PR001 (GBA1 gene therapy) | | | | | | | | | |
| AK-OTOF | OTOF hearing loss | | | I | | | | | |
| LY518674 | Type 2 Diabetes | PPAR | 1 | II | | | | | |
| LY2599506 | Type 2 Diabetes | GKA | OSIP | I | | | | | |
| Zyprexa Depot | Schizophrenia, Bipolar Disorder | Atypical | 1 | Non-Approvable | 2018 | | | | |
| | | | | | | | | | |
| 1/2021: Prevail acquisition | | | 2/6/24: Q423 results. | | | | | | |
| | | | 12/27/23: Completes acquisition of POINT Biopharma (12.50 * ~100m shares) | | | | | | |